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Abstract 
Rationale: Adoptive T cell therapy depends on the harvesting of the cells from the host, their activation in vitro, and their infusion 
back to the same host. The way of activating the T cells in vitro is a critical factor for their homing, survival and function in vivo. 
Sustaining T cell homing molecules, particularly CD62L, is benefic for the trafficking of the adoptive transferred cells.  
Objective: The aim of the present study is to test whether insulin-like growth factor-1 (IGF-1), thymosin- α1 (T-α1) as well as all-
trans retinoid acid (ATRA) alone or in combination with IL-2, IL-12, IL-15 can enhance the activation and survival phenotypes of 
antigen-activated T cells in vitro.  
Methods & Results: To this end, OT-1 transgenic T cells were used as a model. These CD8+ T cells recognize OVA peptide 
presented by MHC class-I. The results showed that antigen stimulation of OT1 cells resulted in their activation as evidenced by the 
decrease in surface expression of CD62L, analyzed for 3 days after antigen stimulation and was more pronounced on day 5. The 
addition of IL-12 or IGF-1 alone but not of IL-2, IL-15 augmented OT-1 cell activation measured on day 5. Interestingly, the 
combination of IL-12 with IGF-1 sustained the expression of CD62L on OT1 cells. Although the addition of ATRA alone or in 
combination with IL-12 resulted in decreases in CD62L expression on day 3, they showed a dose-dependent effect on the restoration 
of CD62L expression on day 5. The analysis of the activation-induced cell death (apoptosis) of OT1 cells showed an increased rate 
of death on day 5 than on day 3-post antigen stimulation. The addition of only IL-12 or IGF-1 alone, but not of IL-2, IL-15 or T- α1, 
decreased OT1 cell apoptosis on day 3. These anti-apoptotic effects of IL-12 and IGF- 1, however, were recovered on day 5-post 
stimulation.  
Discussion: In conclusion, these results indicate that the activation phenotype and the survival of antigen-specific T cells can be 
differently modulated by immunomodulatory factors, where, interleukin-12 and IGF-1 induced the favorable effect. These results 
have a significant implication for T cell adoptive immunotherapy in different settings. 
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Introduction 
Adoptive cell transfer (ACT) represents an 
important advance in cancer immunotherapy. The 
success of ACT depends on the functional quality of cells 
transferred [1]. Upon antigen (Ag) recognition, early 
effector CD8+ T cells are characterized by the expression 
of high levels of the lymphoid homing molecule CD62L or 
L-selectin. The expression of CD62L decreases together 
with the activation progresses, with a re-expression 
almost restricted to central memory cells [2-3]. It is 
believed that the enhanced anti-Ag activity associated 
with T cells expressing high levels of CD62L, related to 
their ability to home the secondary lymph nodes, where 
effective stimulation can take place [4]. Thus, approaches 
aimed at the generation and maintenance of early effector 
populations could be valuable in the development of 
effective ACT-based immunotherapies for cancer. 
Because cytokines are known to play fundamental roles in 
the differentiation and maturation of Ag reactive T cells, 
cytokine conditioning prior to cell transfer has been 
considered as a means of increasing the proliferation and 
function of these cells [5]. Interleukin-2 and interleukin-15 
(IL-2, IL-15) are key participants in T and NK cell 
activation and function [6]. Sharing the beta and gamma-
receptor subunits, such as the promotion of T cell 
proliferation, results in several common functions. On the 
other hand, due to their distinct alpha-receptor subunits, 
they also play opposing roles in immune processes such 
as activation-inducing cell death [6]. 
           However,  IL-2 and IL-15 could both induce 
apoptosis and survival; the outcome depends on the Journal of Medicine and Life Vol. 4, Issue 4, October‐December 2011 
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cytokine concentration [7]. Of significant interest is the 
role of IL-12. In addition to its role in polarizing Th1 
responses and in the maturation of cytotoxic function of 
NK cells [8], IL-12 acts as a third signal along with Ag and 
IL-2 on naïve CD8+ T cells, increasing the pool of effector 
and memory cells, two crucial components of a successful 
ACT approach [9-10]. Evidence for this has been provided 
in recent reports demonstrating increased anti-tumor 
capabilities of CD8+ T cells after ex vivo and  in  vitro 
culture in the presence of IL-12 [11-12]. 
          Increasing  evidence  indicated  that  insulin-like 
growth factor-1 (IGF-1) is involved in the function and 
development of the immune system. IGF-1 may alter 
homeostasis in the immune system by modulating 
lymphocyte generation and survival [13]. 
          In vivo treatment with IGF-1 enhanced thymic 
reconstitution in steroid-treated [14], aged [15], and 
diabetic [16] animals. Hettmer et al. [17] suggested a role 
for IGF binding protein as a local growth factor 
contributing to the proliferation and activation of 
mononuclear cells. The role of IGF-1 in the regulation of 
apoptosis has also been suggested both in vivo and in 
vitro  [18]. The production of IGF-1 by thymic epithelial 
cells [19] and the increased IGF-1 receptor expression on 
T cells after in vitro activation with anti-CD3 antibody [20] 
suggested that IGF-1 may play a role in the T cell 
selection process. 
          Thymosin-α1 (T-α1), initially isolated from thymus, 
is now proved to be effective in inhibiting tumoral growth 
and in controlling infective diseases. Different studies 
evaluated its immunomodulating effects and showed that 
T- α1 increased major histocompatibility complex (MHC) 
class-1, antagonized dexamethasone-induced apoptosis 
of CD4+CD8+ thymocytes [21], primed dendritic cells for 
antifungal T-helper type 1 resistance through Toll-like 
receptor signaling [22], reduced pancreatic inflammation 
by regulating differentiation of CD3/CD4+ T cells [23] and 
increased cytokine production. Vitamin A and its 
metabolite all transretinoic acid (ATRA) have attracted 
considerable attention as compounds that have a broad 
range of immune modulating effects on both humoral and 
cellular immune responses. It was demonstrated that the 
topical retinoids have significant anti-inflammatory effects 
in experimental trials [24]. While ATRA downregulated the 
proinflammatory cytokines, the production of immune 
modulating cytokines was enhanced by ATRA [25]. ATRA 
induced a "priming" of the immune system by increasing 
the number of T lymphocytes and LPS binding protein 
expression [26], and stimulated T cell proliferation by 
modulating IL-2-mediated signaling [27]. ATRA has been 
used as monotherapy for treatment of cutaneous T-cell 
lymphomas for years [28]. The combination of ATRA and 
IFN-gamma could become an efficacious 
chemoimmunotherapy for the treatment of human 
glioblastoma [29]. ATRA also showed potent effects on 
hemopoietic stem cell integrity, inhibiting the expansion of 
human progenitor cells and accelerating their 
differentiation to B lineage cells [30]. 
          The aim of the present study was to define the 
immunomodulatory factors that can increase survival and 
sustain CD62L expression in antigen-specific T cells. To 
this end, the effects of IL-2, IL-12, IL-15, IGF-1, T- α1 as 
well as ATRA alone or in combination were tested in vitro 
utilizing OT1 transgenic T cells as a model. 
Materials and methods 
          Mice: OT-1 T cell receptor (TCR) transgenic mice 
on C57Bl/6 (B6) background were purchased from 
Jackson Laboratory (Bar Harbor, ME). OT-1 mice were 
bred with B6.SJL mice to generate Ly5.1+/Ly5.1+ mice 
heterozygous for the OT-1 TCR (Vα2/Vα5)  transgene 
confirmed by flow cytometry with monoclonal antibody 
(mAb) specific for Vα2. All animals were housed under 
specific pathogen-free conditions in accordance with 
institutional and federal guidelines at the Medical 
University of South Carolina, USA. 
 
          Antibodies  and  reagents:  Anti-CD16/CD32, and 
FITC-, PE-, APC-, and cychrome-conjugated monoclonal 
antibodies (mAbs) were purchased from Pharmingen, San 
Diego, CA. The major histocompatability (MHC) class-I 
SIINFEKL  OVA peptide (OVAp) (American Peptide 
Company, Inc., Sunnyvale, CA) was dissolved  in 10% 
DMSO (Sigma, St. Louis, MO) and diluted in phosphate 
buffered solution (PBS). Cytokines IL-2, IL-12, and IL-15 
(Systems, Minneopolis, MN) were stored as a lyophilized 
powder at -20°C, and reconstituted immediately prior to 
use in 0.1% bovine serum albumin (BSA) in PBS. IGF-1, 
T-α1, and ATRA were purchased from Sigma, San Diego, 
CA. 
 
           Antigen-induced  T  cell  activation:  OT-1 cells 
were prepared and cultured as previously described by 
Salem  et al. [31]. In  brief, one or 2 OT-1 mice were 
sacrificed and spleens and peripheral (cervical, auxiliary, 
brachial, and inguinal) and mesenteric lymph nodes were 
harvested and pooled. Single cell  suspension was 
prepared in PBS by grinding these tissues between the 2 
rough ends of  microscopic slides. Cells were washed 
twice and re-suspended in RPMI medium. Unfractionated 
OT-1 cells (1 x 105) were cultured in triplicate in 6-well 
plate for 3 days in RPMI  medium containing 1 μg/ml 
OVAp and the tested growth factors at the dose indicated 
in  each experiment. Cells were harvested and  washed 
twice and were freshly processed for  the activation 
phenotype and apoptosis measured by flow cytometry. 
 
           Measuring T cell activation by flow cytometry: 
Staining for flow cytometry was performed as previously 
described by Salem et al. [31]. Fresh cells (0.5-1 x 106) 
were treated with anti-CD16/CD32 for 5 minutes on ice 
and then stained with the indicated conjugated mAbs, and Journal of Medicine and Life Vol. 4, Issue 4, October‐December 2011 
  401 © 2011, Carol Davila University Foundation
incubated for 30 min on ice. The cells were washed twice 
and resuspended in 0.3 ml of 0.5% BSA, 0.02% sodium 
azide solution. Cells were washed, and analyzed by flow 
cytometry using the Cell Quest software package (Becton 
Dickinson, San Jose, CA). 
 
           Measuring  apoptosis by flow cytometry: To 
measure apoptosis, cells were stained for the surface 
markers as described above and cells were then washed 
twice with FCAS buffer and twice with Annexin-V binding 
buffer (Pharmingen). Cells were incubated at room 
temperature for 15 minutes and then washed and 
analyzed immediately by flow cytometry. 
Results 
          CD8+ T cells stimulated with Ag showed higher 
levels of CD69 and lower levels of CD62L expression, 
compared to the CD69 and CD62L expression on 
unstimulated CD8+ T cells, on day 3 indicating their 
simulation. Of Note, the decrease in CD62L expression 
after Ag stimulation was further augmented on day 5 post-
stimulation. Addition of IL-2, IL-12 or IL- 15 to CD8+ T 
cells culture during Ag stimulation did not alter the 
phenotypic activation of CD8+ T cells when cells were 
harvested on day 3. The expression of CD62L assessed 
on CD8+ T cells on day 5 was much lower than on day 3. 
However, only CD8+ T cells that had conditioned with IL-
12 showed higher levels of CD62L (Fig. 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Addition of IGF-1 alone or in combination with IL-
2, IL-12 or IL-15 to CD8+ T cells culture during Ag 
stimulation did not significantly alter the expression of 
either CD69 or CD62L on CD8+ T cells on day 3. The 
expression of CD62L assessed on CD8+ T cells on day 5 
was much lower than on day 3. However, only CD8+ T 
cells that had been conditioned with combined IGF-1 and 
IL-12 showed higher levels of CD62L expression. The 
magnitude of this increase reached about 6-folds of the 
corresponding values of Ag stimulated CD8+ T cells (Fig. 
2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Addition of T-α1 alone or in combination with IL-
2, IL-12 or IL-15 to CD8+ T cells culture during Ag 
stimulation did not alter the expression of either CD69 or 
CD62L on CD8+ T cells on day 3. The expression of 
CD62L assessed on CD8+ T cells on day 5 was much 
lower than on day 3. However, only CD8+ T cells that had 
been conditioned with T-α1 and IL-12 in combination 
showed higher levels of CD62L expression. The 
magnitude of this increase reached about 3-folds of the 
corresponding values of Ag-stimulated CD8+ T cells (Fig. 
3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Impacts of cytokines on the antigen-specific activation 
of CD8+ T cells. OT-1 (CD8+) T cells were harvested from 
spleen and LN of naïve TCR transgenic mice and 1 x 106 
cells were cultured in RPMI medium and stimulated with the 
MHC class-I peptide (SIINFEKL) from OVA albumin in the 
presence or absence of 10 ng/ml of interleukin (IL)-2, IL-12, 
or IL-15 cytokines. Cells were harvested on day 3 to assay 
expression of the early activation receptors CD69 and 
CD62L (A) and on day 5 to analyze the expression of only 
CD62L (B). 
Fig. 2 Impacts of cytokines on the activation induced cell 
death of antigen-stimulated CD8+ T cells. OT-1 (CD8+) T 
cells were harvested from spleen and LN of naïve TCR 
transgenic mice and 1 x 106 cells were cultured in RPMI 
medium and stimulated with the MHC class-I peptide 
SIINFEKL from OVA albumin in the presence or absence of 
10 ng/ml of IL-2, IL-12, or IL-15 cytokines. Cells were 
harvested on days 3 and 5 and their early apoptosis was 
analyzed by annexin-v assay. 
Fig. 3 Impacts of a combinatorial treatment with IGF and 
cytokines on the antigen-specific activation of CD8+ T cells 
were harvested from spleen and LN of naïve TCR 
transgenic mice and 1 x 106 cells were cultured in RPMI 
medium and stimulated with the MHC class-I peptide 
SIINFEKL from OVA albumin in the presence or absence of 
10ng/ml insulin growth factor (IGF). Then, cells stimulated 
with IGF were further conditioned with either 10ng/ml IL-2, 
IL-12, or IL-15 cytokines. Cells were harvested on day 3 to 
assay expression of the early activation receptors CD62L 
and CD69 (A) and on day 5 to analyze the expression of 
only CD62L (B). Journal of Medicine and Life Vol. 4, Issue 4, October‐December 2011 
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Addition of ATRA with doses 1, 5, 10 or 15 μM to 
CD8+ T cells culture during Ag stimulation did not alter the 
expression of CD62L on CD8+ T cells on day 3. The 
expression of CD62L assessed on CD8+ T cells on day 5 
was much lower than on day 3. However, only CD8+ T 
cells that had been conditioned with ATRA with doses 10 
and 15 μM showed higher levels of CD62L expression. 
The magnitude of this increase reached about 2.8- and 3-
folds of the corresponding values of Ag-stimulated CD8+ 
T cells, respectively (Fig. 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Addition of ATRA with doses 1, 5, 10 or 15 μM in 
combination with IL-12 to CD8+ T cells culture during Ag 
stimulation did not alter the expression of CD62L on 
CD8+ T cells on day 3. The expression of CD62L 
assessed on CD8+ T cells on day 5 was much lower than 
on day 3. However, only CD8+ T cells that had been 
conditioned with ATRA with doses 5, 10 and 15 μM 
showed higher levels of CD62L expression. The 
magnitude of this increase reached about 2.7-, 3- and 3.7-
folds of the corresponding values of Ag-stimulated CD8+ 
T cells, respectively (Fig. 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To test whether conditioning CD8+ T cells with 
IL-2, IL-12 or IL-15 impacts on Ag-induced T cells 
apoptosis, expression of Annexin V, as a marker of 
apoptosis, was measured by flow cytometry. It was found 
that stimulation of cells with Ag alone induced about 40% 
of the cultured cells to undergo apoptosis on day 3, which 
further augmented on day 5. Treatment of CD8+ T cells 
with only IL-12, but not IL-2 or IL-15 decreased the 
apoptosis level of CD8+ T cells by about 41% of the 
corresponding value of Ag-stimulated CD8+ T cells when 
measured on day 3. This anti-apoptotic effect of IL-12, 
however, was lost by day 5 (Fig. 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment of CD8+ T cells with IGF-1 alone or in 
combination with IL-12 or IL-15, but not IL-2, decreased 
the percentage of apoptosis of these cells by about 51.1 
and 62.9% of the corresponding value of Ag-stimulated 
CD8+ T cells, respectively, when measured on day 3. 
However, the anti-apoptotic effect of IGF-1 alone or in 
combination with IL-12 or IL-15 was less pronounced on 
day 5 (Fig. 7). 
 
Fig. 4 Impacts of a combinational treatment with IGF and 
cytokines on the antigen-specific activation of CD8+ T cells. 
OT-1 (CD8+) T cells were harvested from spleen and LN of 
naïve TCR transgenic mice and 1 x 106 cells were cultured 
in RPMI medium and stimulated with the MHC class-I 
peptide SIINFEKL from OVA albumin in the presence or 
absence of 10ng/ml insulin growth factor (IGF). Cells 
stimulated with IGF were also conditioned with either 10 
ng/ml IL-2, IL-12, or IL-15 cytokines. Cells were harvested 
on days 3 and 5 and their early apoptosis was analyzed by 
annexin-v assay. 
Fig. 5 Impacts of a combinatorial treatment with thymosin 
and cytokines on the antigen-specific activation of CD8+ T 
cells. OT-1 (CD8+) T cells were harvested from spleen and 
LN of naïve TCR transgenic mice and 1 x 106 cells were 
cultured in RPMI medium and stimulated with the MHC 
class-I peptide SIINFEKL from OVA albumin in the presence 
or absence of 10 ng/ml thymosin (Thym). Cells stimulated 
with Thym were also conditioned with either 10 ng/ml IL-2, 
IL-12, or IL-15 cytokines. Cells were harvested on day 3 to 
assay expression of the early activation receptors CD62L 
and CD69 (A) and on day 5 to analyze the expression of 
only CD62L (B). 
Fig. 6 Impacts of a combinational treatment with Thym and 
cytokines on the antigen-specific activation of CD8+ T cells. 
OT-1 (CD8+) T cells were harvested from spleen and LN of 
naïve TCR transgenic mice and 1 x 106 cells were cultured 
in RPMI medium and stimulated with the MHC class-I 
peptide SIINFEKL from OVA albumin in the presence or 
absence of 10 ng/ml thymosin (Thym). Cells stimulated with 
Thym were also conditioned with either 10 ng/ml, IL-2, IL-12, 
or IL-15 cytokines. Cells were harvested on days 3 and 5 
and their early apoptosis was analyzed by annexin-v assay. Journal of Medicine and Life Vol. 4, Issue 4, October‐December 2011 
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Combined treatment of CD8+ T cells with only T-
α1 and IL-12, but not T-α1 alone or in combination with 
IL-2 or IL-15, decreased the percentage of apoptosis of 
these cells by about 47.5% of the corresponding value of 
Agstimulated CD8+ T cells when measured on day 3. 
However, the anti-apoptotic effect of a combined 
treatment with T-α1 and IL-12 was less pronounced by 
day 5 (Fig. 8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment of CD8+ T cells with ATRA (1 and 10 
μM), but not 5 or 15 μg, decreased the percentage of 
apoptosis of these cells by about 49.2 and 44.7% of the 
corresponding value of Ag-stimulated CD8+ T cells, 
respectively when measured on day 3. However, the anti-
apoptotic effect of ATRA treatment with doses 1 and 10 
μg was abrogated by day 5 (Fig. 9a). Combined treatment 
of CD8+ T cells with ATRA (1, 5, 10 and 15 μM) and IL-12 
decreased the percentage of apoptosis of these cells by 
about 67.0, 70.1, 66.5 and 65.8% of the corresponding 
value of Ag-stimulated CD8+ T cells, respectively when 
measured on day 3. However, the anti-apoptotic effect of 
a combined treatment of ATRA with doses 1, 5, 10 and 15 
μM and IL-12 was recovered by day 5 (Fig. 9b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
CD8+ T cells are a critical component of the 
cellular immune response. They play an important role in 
the control of viral infection and eliminating cells with 
malignant potential [32-33]. However, attempts to 
generate and expand human CD8+ T cells in vitro for an 
adoptive immunotherapy had been conducted with 
limitation of the very low frequency of CD8+ T cells in 
blood. Therefore, several expansion protocols were 
developed to obtain large and efficient numbers of human 
CD8+ T cells for use in adoptive immunotherapies [34]. In 
this study IL-12 alone, but not IL-2 nor IL-15, as well as 
IGF-1 alone augmented the activation of CD8+ OT1 T 
cells. Interestingly, combination of IL -12 with IGF-1 
Fig. 7 Impacts of treatment with different concentration of 
ATRA on the antigen-specific activation of CD8+ T cells. 
OT-1 (CD8+) T cells were harvested from spleen and LN of 
naïve TCR transgenic mice and 1 x 106 cells were cultured 
in RPMI medium and stimulated with the MHC class-I 
peptide SIINFEKL from OVA albumin in the presence or 
absence of the indicated concentrations of ATRA. Cells 
were harvested on day 3 to assay expression of the early 
activation receptors CD62L and CD69 (A) and on day 5 to 
analyze the expression of only CD62L (B). 
 
Fig. 8 Impacts of a combinatorial treatment with ATRA and 
IL-12 on the antigen-specific activation of CD8+ T cells. OT-
1 (CD8+) T cells were harvested from spleen and LN of 
naïve TCR transgenic mice and 1 x 106 cells were cultured 
in RPMI medium and stimulated with the MHC class-I 
peptide SIINFEKL from OVA albumin in the presence or 
absence of different concentration of ATRA. Cells stimulated 
with ATRA were concomitantly treated with 10 ng/ml IL-12. 
Cells were harvested on day 3 to assay expression of the 
early activation receptors CD62L and CD69 (A) and on day 
5 to analyze the expression of only CD62L (B). 
Fig. 9 Impacts of treatment with ATRA alone or in 
combinational with IL-12 on the antigen-specific activation of 
CD8+ T cells. OT-1 (CD8+) T cells were harvested from 
spleen and LN of naïve TCR transgenic mice and 1 x 106 
cells were cultured in RPMI medium and stimulated with the 
MHC class-I peptide SIINFEKL from OVA albumin in the 
presence or absence of different concentration of ATRA (A). 
A separate set of ATRA-treated cells were concomitantly 
treated with 10 ng/ml IL-12 (B). Cells were harvested on day 
5 post treatment and their apoptosis was determined by 
annexin-v binding assay. Journal of Medicine and Life Vol. 4, Issue 4, October‐December 2011 
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sustained the expression of CD62L on OT1 cells. Analysis 
of the activation-induced cell death (apoptosis) of OT1 
cells showed that addition of only IL-12 or IGF-1 alone, 
but not IL-2, IL-15 or T-α1, to Ag-stimulated CD8+ T cells 
decreased the percentage of apoptosis of these cells.  
In vitro or in vivo treatment with IL-12 resulted in 
enhanced activity of T and NK cells which is characterized 
by increased secretion of IFN-γ [ 31]. Such enhanced 
immune response is, in part, the result of the direct 
stimulation of antigen presenting cells. A previous study 
by Salem et al. [35] showed that paracrine administration 
of IL-12 enhanced the functional capability of spleen 
dendritic cells to present peptide to naïve CD8+ T cells. 
IL-12 can also directly affect the development of CD8+ T 
cell-mediated responses [32]. By signaling directly 
through its receptor on CD8 T cells, IL-12 influences their 
differentiation to favor the generation of fully activated 
effectors [34]. It is known that optimal clonal expansion 
and acquisition of effector function requires a third signal 
that can be provided by IL-12 and that, in the absence of 
third signal, tolerance can occur [9-10]. In support of these 
findings, Chang et al. [36] reported that IL-12 priming at 
the time of antigenic stimulation increased the primary 
expansion of CD8+ T cells by reducing cell death, rather 
that by increasing cell proliferation, resulting in a larger 
CD8+ T cell memory pool. The ability of IL-12 to enhance 
proliferation of activated CD8+ T cells has been 
associated with enhanced expression of IL-2Rα in 
response to IL-12R engagement [10]. IL-12R expression 
is upregulated upon T cell receptor (TCR) activation [37], 
however low levels of expression were reported in resting 
NK cells, dendritic cells and B cell lines [38-39]. 
Historically, the expression of IL-12R was confined to 
activated Th1 cells [40-41], however the pivotal role of IL-
12 in providing third signal for the clonal expansion of 
naïve CD8+ T cells, demonstrates a similar pattern of 
expression on activated CD8+ T cells [10]. 
            IGF-1 has been implicated to play a regulatory role 
in T cell development and in T cell function [42]. In vivo 
activated T lymphocytes exhibit altered expression of IGF- 
1 receptor compared to the naïve T lymphocyte pool [43]. 
IGF-1 receptors were readily detectable on a wide variety 
of the immune cells, including T cells, B cells and 
monocytes, but the binding capacity for IGF-1 was 
monocytes, B cells and T cells. The level of IGF-1 
receptor expression was increased several-fold after 
stimulation of both CD4+ and CD8+ T-cell subsets. IGF-1 
is also expressed in many tumor cell lines and had a role 
in both normal cell proliferation and in the growth of 
cancers. Several approaches to target IGF-1 signaling 
resulted in the inhibition of the growth of a broad range of 
tumor cells [44]. IGF-1 was shown to protect cells from 
apoptosis by different stimuli and conditions [45]. It may 
alter homeostasis in the immune system by modulating 
lymphocyte generation and survival [13].  
            Mice deficient in dendritic epidermal T cells had a 
notable increase in epidermal apoptosis that was 
abrogated by the addition of IGF-1 [46]. T cell death-
associated gene 51 plays an important role in the anti-
apoptotic effects of IGF-I. Thus, effective strategies to 
generate competent CD8+ T cells for adoptive transfer 
should promote not only the generation of key 
subpopulations with superior anti-tumor activity, but also 
the maintenance of their viability in vivo. The present 
results suggest that antigen priming in the presence of 
both IL- 12 and IGF-1 accomplishes both ends. It not only 
directly modulates the expression of CD62L on activated 
CD8+ T cells, but also selectively promotes the survival of 
activated CD8+ T cells expressing high levels of CD62L. 
In conclusion, the present results indicate that the 
activation phenotype and the survival of antigen-specific T 
cells can be differentially modulated by different 
immunomodulatory factors, where, interleukin- 12 and 
IGF-1 induced the favorable effect. These results have a 
significant implication for T cell adoptive immunotherapy 
in different settings. 
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